MP85-01 RISK OF MELANOMA WITH PHOSPHODIESTERASE TYPE 5 INHIBITOR USE AMONGST PATIENTS WITH ERECTILE DYSFUNCTION, PULMONARY HYPERTENSION AND LOWER URINARY TRACT SYMPTOMS

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II1 Apr 2018MP85-01 RISK OF MELANOMA WITH PHOSPHODIESTERASE TYPE 5 INHIBITOR USE AMONGST PATIENTS WITH ERECTILE DYSFUNCTION, PULMONARY HYPERTENSION AND LOWER URINARY TRACT SYMPTOMS Eugene Shkolyar, Shufeng Li, Jean Tang, and Michael Eisenberg Eugene ShkolyarEugene Shkolyar More articles by this author , Shufeng LiShufeng Li More articles by this author , Jean TangJean Tang More articles by this author , and Michael EisenbergMichael Eisenberg More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2861AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Phosphodiesterase type 5 inhibitors (PDE5i), a treatment for erectile dysfunction (ED), pulmonary hypertension (pHTN) and lower urinary tract symptoms (LUTS), have been implicated in melanoma development. Prior studies have been limited to men prescribed PDE5i for ED. We sought to determine the association between PDE5i use and melanoma development amongst all patients with ED, pHTN and LUTS. We also sought to determine if PDE5i use had any impact on melanoma treatment once diagnosed. METHODS Retrospective cohort study of subjects contained within the Truven Health MarketScan claims database, which provides information on insurance claims in the US for privately-insured individuals, from 2007 to 2015. Individuals taking PDE5i were identified through pharmacy claims. A comparison group of subjects diagnosed with conditions for which PDE5i are prescribed was assembled. Cox proportional hazard models were used to estimate the hazard ratio (HR) (95% CI) of incident melanoma, basal cell carcinoma, squamous cell carcinoma. RESULTS Of 610,881 subjects prescribed PDE5i, 636 developed melanoma (0.10%). There was an association between increased PDE5i tab use and melanoma (HR 1.05, 95% CI 1.05-1.09). This association was also present between PDE5i use and basal cell carcinoma (HR 1.04, 95% CI 1.02-1.07), and squamous cell carcinoma (HR 1.04, 95% CI 1.01-1.07). In patients with pHTN and LUTS prescribed PDE5i, there was no relationship between exposure and melanoma incidence (HR 0.74, 95% CI 0.48-1.13) and (HR 1.03, 95% CI 0.97-1.10), respectively. We found no association between PDE5i use and melanoma amongst female study subjects. There was no difference in melanoma treatment intensity when accounting for PDE5i use, however men taking PDE5i diagnosed with melanoma had longer follow-up times and a higher number of clinic visits (p < 0.0001). CONCLUSIONS There is a slight association between higher volume PDE5i use and development of melanoma, basal cell carcinoma, and squamous cell carcinoma. This association amongst all skin cancers implies that confounding and increased interaction with healthcare providers may account for the observed association. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1169 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Eugene Shkolyar More articles by this author Shufeng Li More articles by this author Jean Tang More articles by this author Michael Eisenberg More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...